Abstract
A glutathione S-transferase (GST) P1 polymorphism results in an amino acid substitution, Ile105Val; the Val-containing enzyme has reduced activity toward alkylating agents. Cancer patients with the variant enzyme may differ in removal of treatment agents and in outcomes of therapy. We evaluated survival according to GSTP1 genotype among women (n = 240) treated for breast cancer. Women with the low-activity Val/Val genotype had better survival. Compared with Ile/Ile, hazard ratios for overall survival were 0.8 (95% confidence interval, 0.5-1.3) for Ile/Val and 0.3 (95% confidence interval, 0.1-1.0) for Val/Val (P for trend = 0.04). Inherited metabolic variability may influence treatment outcomes.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Amino Acid Substitution / genetics
-
Breast Neoplasms / enzymology*
-
Breast Neoplasms / genetics
-
Breast Neoplasms / mortality*
-
Breast Neoplasms / therapy
-
Disease-Free Survival
-
Female
-
Genotype
-
Glutathione S-Transferase pi
-
Glutathione Transferase / genetics*
-
Glutathione Transferase / metabolism
-
Humans
-
Isoenzymes / genetics*
-
Isoenzymes / metabolism
-
Isoleucine / genetics
-
Middle Aged
-
Polymorphism, Genetic
-
Proportional Hazards Models
-
Receptors, Estrogen / physiology
-
Survival Analysis
-
Treatment Outcome
-
Valine / genetics
Substances
-
Isoenzymes
-
Receptors, Estrogen
-
Isoleucine
-
GSTP1 protein, human
-
Glutathione S-Transferase pi
-
Glutathione Transferase
-
Valine